Aethlon Medical’s (AEMD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the medical equipment provider’s stock.

Separately, StockNews.com began coverage on Aethlon Medical in a report on Monday. They set a “sell” rating for the company.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.73 on Thursday. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.88. The company’s 50-day moving average price is $0.56 and its two-hundred day moving average price is $0.45.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.